News Articles Tagged: CCK-2 Receptor Antagonist

From Lab to Clinic: The Journey of Nastorazepide as a Pharmaceutical Intermediate by NINGBO INNO PHARMCHEM CO.,LTD.

NINGBO INNO PHARMCHEM CO.,LTD. discusses Nastorazepide's transition from a research compound to a pharmaceutical intermediate, emphasizing its role in developing new treatments for cancer and other conditions.

The Pharmaceutical Significance of Nastorazepide (Z-360): An API for Advanced Research by NINGBO INNO PHARMCHEM CO.,LTD.

NINGBO INNO PHARMCHEM CO.,LTD. highlights Nastorazepide (Z-360) as a critical Active Pharmaceutical Ingredient (API) for advanced research, focusing on its CCK-2 receptor antagonism and potential in cancer therapy development.

Exploring Nastorazepide: A Deep Dive into CCK-2 Receptor Antagonism and Its Applications by NINGBO INNO PHARMCHEM CO.,LTD.

NINGBO INNO PHARMCHEM CO.,LTD. provides an in-depth look at Nastorazepide (Z-360), focusing on its function as a CCK-2 receptor antagonist and its diverse applications in research, including potential in pain relief and metastasis inhibition.

The Role of Nastorazepide in Advanced Pancreatic Cancer Treatment: A Scientific Overview by NINGBO INNO PHARMCHEM CO.,LTD.

NINGBO INNO PHARMCHEM CO.,LTD. explores the scientific basis of Nastorazepide (Z-360) as a CCK-2 receptor antagonist and its emerging role in pancreatic cancer therapy, including combination strategies.